On December 2, 2024, Inari Medical, Inc. (Inari), a medical device company, announced it has entered into a joint venture with 6 Dimensions Capital (6 Dimensions) and its successor fund 120 Capital, and VFLO Medical (VFLO), a medical device platform incubated by 6 Dimensions and 120 Capital, to provide access to Inari’s innovative technology for patients with significant unmet needs in Greater China. On December 3, 2024, VFLO Medical also announced the strategic cooperation with Inari as well as its $80 million Series B financing with participation from 6 Dimensions, 120 Capital, and certain other investors.

The joint venture will allow Inari to commercialize its devices through VFLO’s established infrastructure, local relationships, and deep commercial expertise in Greater China. VFLO will also have the right to use Inari’s technology to manufacture products, including ClotTriever and FlowTriever, for domestic sale in Greater China.

Wilson Sonsini Goodrich & Rosati represented 6 Dimensions and VFLO in this transaction. The team includes:

Corporate
Jie Zhu
Xuchao Dong
Athena Yu
Yi Shen
Yiwen Feng

Technology Transactions
Ian B. Edvalson
Magnus Gan

For more information, please see Inari’s press release and 6 Dimensions’ press release.